Biventricular assist device (BiVAD) support was a strong predictor of early mortality in the Berlin Heart EXCOR Pediatric investigational device exemption (IDE) study (Assess Safety and Probable Benefit of the EXCOR Pediatric Ventricular Assist Device [VAD]).

The use of BHE could successfully bridge pediatric patients till the OHTx, but the management of small patients is especially challenging. In fact, small body surface area seems to be associated with an increased risk of thromboembolic complications during VAD assistance and increased mortality as reported by Almond et al. (2013).

EXCOR ® Pediatric is a mechanical circulatory support system that provides assistance to the failing left ventricle. The system is specifically designed for infants and children with life-threatening heart failure refractory to optimal medical therapy.

Early implantation of pulsatile BiVAD support can be used to bridge pediatric patients with end-stage heart failure to HT with good outcomes and with AE rates comparable with LVAD support alone.

Background: Biventricular assist device (BiVAD) support was a strong predictor of early mortality in the Berlin Heart EXCOR Pediatric investigational device exemption (IDE) study (Assess Safety and Probable Benefit of the EXCOR Pediatric Ventricular Assist Device [VAD]).

Biventricular assist device (BiVAD) patients experienced a 27.3% survival, vs 77.8% for patients with left ventricular assist device only (P = .07). Primary causes of death included stroke, infection, acidosis, multisystem organ failure, and bleeding.

We aimed to show that early BiVAD support can result in good survival by analyzing our prospectively collected database for all pediatric patients who underwent BiVAD implantation. From 2005 to 2009, BiVADs were used exclusively. From 2010 to 2014, LVAD alone was considered, maintaining a low threshold for BiVAD support.

2020年11月1日 · The use of ventricular assist devices has increased in the pediatric population. The differences in biventricular assist device (BiVAD) vs left ventricular assist device (LVAD) outcomes are likely driven by patient characteristics.

2008年9月30日 · Recently, the Berlin Heart EXCOR device became available for use in North America on a compassionate use basis. We describe our experience with biventricular assist device (BiVAD) support using the Berlin Heart pump in 9 pediatric heart transplant candidates.

17 of pediatric patients required BiVAD support, although % there was a downward trend over the final 3 years. This trend likely relates to the recognition that pediatric pa-tients supported by BiVADs have worse survival outcomes and experience more adverse events compared with patients supported with LVADs, a finding recapitulated in this